Rayner Pharmaceuticals Limited Issues Defect Notification for Dropodex 0.1% Eye Drops
Areazine synthesizes this MHRA medicine alert directly from MHRA's official public data feed. See our methodology for full source attribution and refresh cadence.
Rayner Pharmaceuticals Limited has notified the MHRA that certain batches of Dropodex 0.1% w/v Eye Drops fail to list phosphate concentration in the product information.
What this MHRA medicine alert tells you, and what most readers miss
This notice was issued by MHRA on April 6, 2026 and geographically references United Kingdom. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Alerts - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, mhra, pharmaceuticals.
What Happened
Rayner Pharmaceuticals Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of a defect regarding the product information for Dropodex 0.1% w/v Eye Drops. The company reported that the affected batches do not include the specific concentration of phosphates in the provided product documentation.
Which Products Are Affected
The notification applies to the following product:
- Product Name: Dropodex 0.1% w/v Eye Drops, solution
- Manufacturer: Rayner Pharmaceuticals Limited
- Notification Reference: EL(26)A/10
The MHRA has classified this as a Class 4 Medicines Defect Notification, indicating that the issue is not considered a risk to patient safety that would require a full recall of the product from the market.
What You Should Do
As this is a Class 4 notification, it is primarily intended to inform healthcare professionals and patients of the labeling omission. Consumers using this medication should be aware that the phosphate concentration was missing from the current product information. For further information or specific batch inquiries, consumers may refer to the official MHRA alert or contact Rayner Pharmaceuticals Limited.
Why This Matters
This notification ensures transparency regarding the chemical composition of the eye drops. While the omission of phosphate concentration in the labeling is a regulatory defect, the MHRA has categorized the severity of this issue as low, posing minimal safety impact to the public.
Source
Original source: MHRA Official Notice ↗
Related Medicine Alerts
All Medicine Alerts →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this MHRA medicine alert: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,775 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to April 6, 2026.
Frequently Asked Questions
Common questions about this MHRA medicine alert.